LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Molina Healthcare Senior Executive Vice President and CFO Mark Keim to Expand Role to Include Leadership of the Medicaid Health Plans and Marketplace Business

September 04, 2024 | Last Trade: US$355.15 2.10 0.59

LONG BEACH, Calif. / Sep 04, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that Senior Executive Vice President and Chief Financial Officer, Mark Keim, will assume an expanded role which will now include leadership of the Company’s Medicaid Health Plans and Marketplace business. His responsibilities as Chief Financial Officer of the enterprise remain unchanged.

Keim, 59, joined Molina in January of 2018 and was named Chief Financial Officer in February 2021.

“Mark has been an extraordinary leader not only in the realm of finance, but also in strategic development and operations," said Molina President and CEO Joe Zubretsky. “Formally extending that leadership and results orientation to our Medicaid and Marketplace businesses is a natural evolution. Mark and Chief Operating Officer Jim Woys lead a very talented and deep operating team which has been the hallmark of our success.”

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.

Astria Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB